COMPANY PROFILE

Candid Therapeutics

Explore full profile

A clinical-stage biotech firm focused on advancing treatments for a range of immunological conditions

San Diego, United StatesFounded 2024Biotech & Life Sciences

Valuation $1–2.5B Last recorded · 2026

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Candid Therapeutics

CandidRx is a biotechnology company focused on developing innovative therapies for autoimmune diseases. The company leverages known biological mechanisms to create novel, easy-to-administer treatments that offer significant benefits to patients. CandidRx operates in the healthcare and life sciences market, primarily serving patients suffering from autoimmune conditions. The company's business model revolves around rigorous scientific research and the development of T cell engager antibodies, which precisely redirect T cells to selectively eliminate autoreactive B cells, aiming for transformative efficacy and safety. Revenue is generated through the development and commercialization of these therapies, supported by investments from prominent stakeholders who share the company's vision. CandidRx's team comprises industry experts with a proven track record in creating stakeholder value. The company is committed to advancing the field of autoimmune therapy through its pioneering approach and deep understanding of immunological mechanisms.

MoreLess Source: Dealroom company data

At a glance

Status: Acquired
Founded: 2024
Headquarters: San Diego, United States
Employees: 32
Open positions: None listed
Dealroom signal: 92.8/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Immunotherapy, Verified Unicorns and $1B Exits, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Investment activity: 1 company, latest Mar 2026
Capital deployed: —
Preferred round: ACQUISITION
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITIONOther financing	May 2026	$2B	$2B	UCB	↗
LATE VCOther financing	Sep 2024	$370M	$1.5B	Polaris Partners · Fidelity Investments · Foresite Capital · Franklin Templeton Investments	↗

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Candid Therapeutics website traffic

Latest recorded traffic for Candid Therapeutics is 3.9K monthly website visits, down 37.1% over the last three months. Candid Therapeutics's team grew 0% over the past year.

Latest monthly visits3.9K 3-month web change-37.1% 1-year team growth0%

Monthly website visitsSep 2024–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ATApogee TherapeuticsDevelops advanced biologics for treating inflammatory and immune diseases like atopic dermatitis and asthma	Waltham, United States	Acquired	340	$169M	$9.3B
VTVera TherapeuticsA clinical-stage biotechnology company focused on transforming patients’ lives by developing and commercializing treatments for immunological and inflammatory diseases	Brisbane, United States	Operational
HBHuman Immunology BiosciencesBiotechnology company focused on developing therapies for immune-mediated diseases	San Francisco, United States	Acquired
MEMetseraMetsera is a clinical-stage biopharmaceutical company dedicated to leading the next generation of medicines and solutions for obesity and metabolic diseases	New York City, United States	Acquired
KTKelonia TherapeuticsDeveloping a new wave of genetic medicines using its next generation vivo gene delivery platform	Boston, United States	Acquired
NTNeumora TherapeuticsPioneering a new era of precision medicines for brain diseases	Waltham, United States	Operational
MIMoonLake ImmunotherapeuticsMoonLake Immunotherapeutics AG is a clinical-stage biopharmaceutical company leveraging revolutionary Nanobody® technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases	Zug, Switzerland	Operational
ABArriVent BiopharmaAccelerating the Global Development of Innovative Biopharmaceutical Products	Upper Merion Township, United States	Operational